Autism: Brain Chain Reaction Linked to Nitric Oxide & Potential New Treatments

A newly discovered molecular chain reaction within the brain may be a key factor in some cases of autism spectrum disorder (ASD), and researchers have identified a potential way to interrupt the process. The findings, published in Molecular Psychiatry, offer a more precise understanding of the biological mechanisms potentially driving ASD and could open new avenues for targeted therapies.

The brain relies on intricate chemical signaling to function properly. Nitric oxide, a molecule involved in this signaling, appears to play a complex role. This research suggests that in certain instances, nitric oxide may inadvertently trigger a cascade of events that disrupt normal brain activity. The study, led by Professor Haitham Amal at the Hebrew University of Jerusalem, focuses on how nitric oxide interacts with a protective protein called TSC2 and a crucial cellular control system known as mTOR.

How Nitric Oxide Impacts Cellular Regulation

Typically, nitric oxide acts as a subtle messenger, helping to fine-tune communication between brain cells. However, the research team discovered that in some cases linked to ASD, nitric oxide may initiate a biochemical process that pushes cellular signaling into overdrive. This process centers around a modification of proteins called S-nitrosylation, where nitric oxide attaches to proteins and alters their function.

The researchers found that proteins connected to the mTOR pathway – a major regulator of cell growth and protein production – were particularly affected by this modification. This led them to investigate TSC2, which normally acts as a “brake” on mTOR activity, maintaining cellular balance. They discovered that nitric oxide can modify TSC2 in a way that signals the protein for removal. As TSC2 levels decline, the braking effect weakens, and mTOR signaling increases. This overactivity of mTOR can disrupt how neurons operate and communicate, potentially contributing to the characteristics associated with ASD. Read the full study in Molecular Psychiatry.

Interrupting the Biochemical Cascade

Encouragingly, the researchers were able to interrupt this process in the lab. By using pharmacological strategies to reduce nitric oxide production in neurons, they prevented the modification of TSC2. MTOR activity returned to normal levels. They also observed improvements in measurements related to protein translation and cellular changes linked to autism in their experimental system. Engineering a version of the TSC2 protein resistant to nitric oxide modification preserved TSC2 levels and reduced the downstream effects of excessive mTOR activity. These results strongly suggest that this specific molecular change may be a significant driver of the pathway.

Clinical Evidence and Genetic Links

To determine if these findings translate to real-world cases, the team analyzed clinical samples from children diagnosed with ASD. These samples came from children with mutations in the SHANK3 gene, as well as those with idiopathic ASD – cases where a single genetic cause isn’t known. The analysis revealed patterns consistent with the laboratory findings: lower levels of TSC2 and increased activity in the mTOR signaling pathway. This suggests the molecular mechanism identified in the lab may also be occurring in individuals with autism.

Understanding Autism Spectrum Disorder

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by differences in social communication and patterns of behavior. It’s a highly diverse condition, with many genetic and biological factors contributing to its development and presentation. The Centers for Disease Control and Prevention (CDC) estimates that approximately 1 in 36 children in the United States are diagnosed with ASD. Learn more about ASD statistics from the CDC. Researchers are increasingly focusing on cellular pathways like mTOR because of their critical role in brain cell growth, adaptation, and the formation of connections.

Implications for Future Research and Treatment

Professor Amal emphasizes that autism is not a single condition with a single cause, and a single pathway is unlikely to explain every case. However, by identifying this clearer chain of events – how nitric oxide-related changes can affect TSC2 and, in turn, mTOR – the research provides a more precise roadmap for future investigations and potential therapeutic strategies. The findings highlight the potential of developing nitric oxide inhibitors as a possible treatment approach for ASD.

A related study published in 2025 by Princeton University and the Simons Foundation identified four distinct subtypes of autism, based on a combination of traits and genetic profiles. This research, published in Nature Genetics, underscores the complexity of ASD and the need for personalized approaches to diagnosis and care. Read more about the autism subtypes research at Princeton.

What’s Next: Refining Therapeutic Targets

The research team plans to continue investigating the specific mechanisms by which nitric oxide affects TSC2 and mTOR. Further studies will explore the potential of different nitric oxide inhibitors and their effects on brain function. Researchers are working to identify biomarkers that could help predict which individuals with ASD might benefit most from therapies targeting this pathway. The Simons Foundation’s SPARK study, which contributed data to the Princeton research on autism subtypes, continues to collect data and provide valuable insights into the genetic and biological underpinnings of ASD. Learn more about the SPARK study.

It’s important to remember that this research is still in its early stages. While the findings are promising, more research is needed to determine whether targeting this pathway will lead to effective treatments for autism. Individuals with concerns about ASD should consult with a qualified healthcare professional for accurate diagnosis and appropriate care.